Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Paolo Tarantino, Biagio Ricciuti, Shan M. Pradhan, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 8, pp. 558-576
Open Access | Times Cited: 119

Showing 1-25 of 119 citing articles:

Exploring the next generation of antibody–drug conjugates
Kyoji Tsuchikama, Yasuaki Anami, Summer Y. Y. Ha, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 203-223
Open Access | Times Cited: 188
Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 186
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Federico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 76
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
A. D'Arienzo, Annarita Verrazzo, Martina Pagliuca, et al.
EClinicalMedicine (2023) Vol. 62, pp. 102113-102113
Open Access | Times Cited: 49
Bispecific antibody drug conjugates: Making 1+1>2
Yilin Gu, Zhijia Wang, Yuxi Wang
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1965-1986
Open Access | Times Cited: 34
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2089-2108
Closed Access | Times Cited: 19
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
Rebecca S. Heist, Jacob Sands, Aditya Bardia, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102720-102720
Open Access | Times Cited: 16
Nanoparticle innovations in targeted cancer therapy: advancements in antibody–drug conjugates
Magdi T. Abdelhamid, Al-Hassan Soliman Wadan, Hosam A. Saad, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 4
ADCdb: the database of antibody–drug conjugates
Liteng Shen, Xiuna Sun, Zhen Chen, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1097-D1109
Open Access | Times Cited: 34
Development of antibody‐drug conjugates in cancer: Overview and prospects
Dan‐Yun Ruan, Hao‐Xiang Wu, Qi Meng, et al.
Cancer Communications (2023) Vol. 44, Iss. 1, pp. 3-22
Open Access | Times Cited: 27
Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates
Liliana Ascione, Lorenzo Guidi, Ajay Prakash, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 12
Tumor-penetrating iRGD facilitates penetration of poly(floxuridine-ketal)-based nanomedicine for enhanced pancreatic cancer therapy
Xingwei Li, Haiping Zhong, Shujing Zheng, et al.
Journal of Controlled Release (2024) Vol. 369, pp. 444-457
Closed Access | Times Cited: 10
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement
Mingxia Jiang, Qiao Li, Binghe Xu
Drug Resistance Updates (2024) Vol. 75, pp. 101086-101086
Closed Access | Times Cited: 9
Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody–Drug Conjugates
Tomohiro Watanabe, Naoko Arashida, Tomohiro Fujii, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 20, pp. 18124-18138
Open Access | Times Cited: 9
Next-generation combination approaches for immune checkpoint therapy
Sangeeta Goswami, Kristen E. Pauken, Linghua Wang, et al.
Nature Immunology (2024) Vol. 25, Iss. 12, pp. 2186-2199
Closed Access | Times Cited: 9
Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies
Sahar Balkhi, Giorgia Bilato, Andrea De Lerma Barbaro, et al.
Vaccines (2025) Vol. 13, Iss. 1, pp. 69-69
Open Access | Times Cited: 1
Management of nausea and vomiting induced by antibody–drug conjugates
Jawhara Farhat, Hitomi Sakai, Junji Tsurutani
Breast Cancer (2025)
Open Access | Times Cited: 1
Understanding the Toxicity Profile of Approved ADCs
P Martínez, Alfonso López de Sá, Cristina Díaz‐Tejeiro, et al.
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 258-258
Open Access | Times Cited: 1
Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report
Yong Wu, Lingfang Xia, Chunyan Song, et al.
Journal of Ovarian Research (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Therapeutic strategies targeting folate receptor α for ovarian cancer
Jia Mai, Limei Wu, Ling Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
HER2-low gastric cancer: is the subgroup targetable?
Keitaro Shimozaki, Shota Fukuoka, Akira Ooki, et al.
ESMO Open (2024) Vol. 9, Iss. 9, pp. 103679-103679
Open Access | Times Cited: 8
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies
Pablo Jiménez-Labaig, Antonio Rullan, Alberto Hernando‐Calvo, et al.
Cancer Treatment Reviews (2024) Vol. 128, pp. 102772-102772
Closed Access | Times Cited: 7
A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy
Xiaozhi Xi, Yanqing Wang, Guiqi An, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 11, pp. 4806-4818
Open Access | Times Cited: 7
Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future
Aryeh Babkoff, Aviad Zick, Ayala Hubert, et al.
ESMO Gastrointestinal Oncology (2024) Vol. 3, pp. 100032-100032
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top